您好, 歡迎來(lái)到化工儀器網(wǎng)! 登錄| 免費(fèi)注冊(cè)| 產(chǎn)品展廳| 收藏商鋪|
當(dāng)前位置:上海一基實(shí)業(yè)有限公司>>生物試劑>>其他生化試劑>> 1207360-89-1GDC-0349 1207360-89-1
產(chǎn)品型號(hào)1207360-89-1
品 牌
廠商性質(zhì)經(jīng)銷商
所 在 地上海市
更新時(shí)間:2024-11-17 15:11:19瀏覽次數(shù):532次
聯(lián)系我時(shí),請(qǐng)告知來(lái)自 化工儀器網(wǎng)GDC-0349 1207360-89-1
GDC0349
分子式:C24H32N6O3 分子量:452.55
產(chǎn)品描述
GDC-0349 是有效的,選擇性的,ATP競(jìng)爭(zhēng)性mTOR抑制劑,Ki為3.8 nM,比作用于PI3Kα和其他266種激酶的抑制效果高790倍。
靶點(diǎn)
IC50
體外研究
GDC-0349 is a potent and selective ATP-competitive inhibitor of mTOR with IC50 ~3.8 nM. It has remarkable selectivity over 266 kinases, including all isoforms of PI3K (less than 25% inhibition when tested at 1 μM against Invitrogen kinase panel).
體內(nèi)研究
GDC-0349 demonstrates pathway modulation and dose-dependent efficacy in mouse xenograft cancer models. When dosed orally once daily in athymic mice in a MCF7-neo/Her2 tumor xenograft model (PI3K mutation), GDC-0349 inhibited tumor growth in a dose-dependent manner. It was also efficacious in other xenograft models, including PC3 (PTEN null) and 786-0 (VHL mutant). GDC-0349 inhibited downstream markers of mTOR, including phospho-4EBP1 and phospho-Akt(S473) in an in vivo PK/PD study in mouse, consistent with an inhibition of both mTORC1 and mTORC2 complexes. Currently GDC-0349 is in Phase I clinical trials to evaluate the safety and tolerability in patients with locally advanced or metastatic solid tumors or Non-Hodgkin's lymphoma.
溶解性
DMSO 91 mg/mL,水 <1 mg/mL,乙醇 6 mg/mL
穩(wěn)定性
2年 -20°C粉狀,6月-80°C溶于DMSO
請(qǐng)輸入賬號(hào)
請(qǐng)輸入密碼
請(qǐng)輸驗(yàn)證碼
以上信息由企業(yè)自行提供,信息內(nèi)容的真實(shí)性、準(zhǔn)確性和合法性由相關(guān)企業(yè)負(fù)責(zé),化工儀器網(wǎng)對(duì)此不承擔(dān)任何保證責(zé)任。
溫馨提示:為規(guī)避購(gòu)買風(fēng)險(xiǎn),建議您在購(gòu)買產(chǎn)品前務(wù)必確認(rèn)供應(yīng)商資質(zhì)及產(chǎn)品質(zhì)量。